No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CTLT240621P55000
- 0.75
- -0.05-6.25%
15min DelayClose Jun 18 16:00 ET
0.80High0.55Low
0.55Open0.80Pre Close426 Volume7.05K Open Interest55.00Strike Price30.66KTurnover49.13%IV1.49%PremiumJun 21, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.75Extrinsic Value100Contract SizeAmericanOptions Type-0.4760Delta0.1944Gamma71.06Leverage Ratio-0.2224Theta-0.0014Rho-33.82Eff Leverage0.0166Vega
Intraday
- 5D
- Daily
News
Barclays Maintains Catalent(CTLT.US) With Hold Rating, Maintains Target Price $47
Barclays analyst Luke Sergott maintains $Catalent(CTLT.US)$ with a hold rating, and maintains the target price at $47.According to TipRanks data, the analyst has a success rate of 42.3% and a total av
Ardena Appoints Jeremie Trochu as Chief Executive Officer
Ardena (the "Company") today announces the retirement of Harry Christiaens, PhD and the subsequent appointment of Jeremie Trochu as Chief Executive...
Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery
Topline Readout Expected in Q4 2024NASHVILLE, Tenn.--(BUSINESS WIRE)--Melt Pharmaceuticals, Inc. ("Melt"), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation,
Express News | NYSE Order Imbalance 740863.0 Shares on Sell Side
Catalent (NYSE:CTLT) Investors Are Sitting on a Loss of 47% If They Invested Three Years Ago
As an investor its worth striving to ensure your overall portfolio beats the market average.
Is Catalent (NYSE:CTLT) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility of prices, but whether you will suffer a permanent loss of capital.'
Comments
I've been on the hunt for a low-risk, yet relatively high-yield investment strategy, and I'm sure many of you feel the same. 🤔While I'm hesitant to dive into stocks like $NVIDIA(NVDA.US$ , fearing the price might be peaking and a sudden drop is imminent, I also find the stable dividends of companies like $Coca-Cola(KO.US$ underwhelming for my limited capital. 💡 But recently, I stumbled upon the concept of diversified investing, wh...
12
The pharma giant $Eli Lilly and Co(LLY.US$ is on the cusp of a significant breakthrough with its Alzheimer's drug, donanemab. Following the completion of its Phase 3 trials, donanemab is currently undergoing FDA review and has the potential to receive approval later this month. If approved, it would be the second anti-Aβ therapy for Alzheimer's disease to receive full clearance from the U.S. FD...
71
$Catalent(CTLT.US$ why drop
$Catalent(CTLT.US$ 👀63$ all set target
RECAP
Stocks Fall as Yields Rise
US stocks fell as yields rose after investors tempered expectations of interest rate cuts this year. Over the weekend, Federal Reserve Chairman Jerome Powell said policymakers are worried that inflation could rear its ugly head and reaccelerate if the central bank moves too soon in lowering borrowing costs.
The $S&P 500 Index(.SPX.US$ slipped 0.3%, while the tech-heavy $NASDAQ 100 Index(.NDX.US$ slid 0...
Stocks Fall as Yields Rise
US stocks fell as yields rose after investors tempered expectations of interest rate cuts this year. Over the weekend, Federal Reserve Chairman Jerome Powell said policymakers are worried that inflation could rear its ugly head and reaccelerate if the central bank moves too soon in lowering borrowing costs.
The $S&P 500 Index(.SPX.US$ slipped 0.3%, while the tech-heavy $NASDAQ 100 Index(.NDX.US$ slid 0...
23
Read more